Neurotech Phase II/III Autism Trial Successfully Meets Primary Endpoint Highlights:
• NTIASD2 Phase II/III clinical trial met the primary endpoint of a statistically significant improvement in severity of illness (CGI-S) at 8 weeks between NTI164 and placebo (p<0.001)
• Children in NTI164 group re-classified from markedly-severely ill (CGI-S: 5.54) at baseline to mild-moderately ill (CGI-S: 3.77) at 8 weeks, a very strong improvement
• Key Secondary endpoints examining adaptive behaviour improvements (Vineland™-3) (p=0.024), CGI-Improvement (p<0.001) social responsiveness (p=0.028), were met with strong treatment-related benefits over placebo
• No serious adverse events recorded, no changes to kidney/liver function over the 8-week period noted, no treatment-related diarrhoea and nausea/vomiting rate lower for NTI164 arm
• Neurotech to accelerate registration-related regulatory discussions given strength of data
• NDIS spend of $6.73 billion to participants with Autism highlights dire need for a safe and effective therapeutic intervention to improve ASD symptoms and reduce healthcare costs
https://www.investi.com.au/api/announcements/nti/3e87a498-65a.pdf
- Forums
- ASX - By Stock
- NTI
- Ann: Phase II/III ASD Trial Successfully Meets Primary Endpoint
Ann: Phase II/III ASD Trial Successfully Meets Primary Endpoint, page-2
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NTI (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.7¢ |
Change
0.006(9.84%) |
Mkt cap ! $68.16M |
Open | High | Low | Value | Volume |
6.1¢ | 7.1¢ | 6.1¢ | $140.1K | 2.120M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 75000 | 6.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.7¢ | 57449 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 75000 | 0.066 |
2 | 284891 | 0.064 |
1 | 10000 | 0.062 |
1 | 54999 | 0.061 |
4 | 147000 | 0.060 |
Price($) | Vol. | No. |
---|---|---|
0.067 | 57449 | 1 |
0.068 | 76841 | 1 |
0.075 | 27637 | 1 |
0.078 | 106680 | 2 |
0.079 | 300000 | 1 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
NTI (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online